Artal Group »

Elevation Oncology shares owned by Artal Group

Quarter-by-quarter ownership of Elevation Oncology (ELEV) shares owned by Artal Group from 13F filings

Historical chart of Artal Group investment in Elevation Oncology

Tip: Access up to 7 years of quarterly data

All positions including Elevation Oncology held by Artal Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Elevation Oncology by Artal Group

Quarter filed Position value Share count Share price at filing
2024-03-31 $7.8M 1.5M 5.13

More positions owned by Artal Group

Cava Group Ord (CAVA)
Lexicon Pharmaceuticals Com New (LXRX)
Scholar Rock Hldg Corp (SRRK)
Kymera Therapeutics (KYMR)
Arrowhead Pharmaceuticals Call Option (ARWR)
Morphic Hldg (MORF)
Apellis Pharmaceuticals (APLS)
Springworks Therapeutics (SWTX)
Crinetics Pharmaceuticals In (CRNX)
Beigene Sponsored Adr (BGNE)
Silence Therapeutics Ads (SLN)
Dyne Therapeutics (DYN)
Revolution Medicines (RVMD)
Kura Oncology (KURA)
Neumora Therapeutics (NMRA)

View all positions for Artal Group

Top funds holding Elevation Oncology

Farallon Capital Management
Point72 Asset Management
Tang Capital Management
Balyasny Asset Management
Aisling Capital Management
venBio Partners
Braidwell
Qiming U.S. Ventures Management
Darwin Global Management
BVF
Citadel Advisors
Vanguard Group
Artal Group
Hudson Bay Capital Management
Palo Alto Investors

View all funds holding Elevation Oncology